Related Experiment Videos

Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic

A J Salsbury, K Burrage, K Hellmann

    British Medical Journal
    |November 7, 1970
    PubMed

    Insights

    The drug I.C.R.F. 159 prevented cancer spread in mice by inhibiting new blood vessel growth in tumors. This novel drug action specifically targeted tumor cell dissemination without affecting primary tumor growth.

    Area of Science:

    • Oncology
    • Cancer Biology
    • Pharmacology

    Background:

    • Metastasis is a complex process involving tumor vascularization and cell dissemination.
    • Lewis lung carcinoma is a common model for studying cancer metastasis.
    • Developing drugs that specifically inhibit metastasis is a critical goal in cancer therapy.

    Purpose of the Study:

    • To investigate the effect of I.C.R.F. 159 on metastasis formation in Lewis lung carcinoma.
    • To determine if I.C.R.F. 159 affects primary tumor growth.
    • To elucidate the mechanism by which I.C.R.F. 159 inhibits metastasis.

    Main Methods:

    • Mice were implanted with Lewis lung carcinoma.
    • Mice were treated with I.C.R.F. 159 at varying doses.
    • Primary tumor growth and metastasis formation were monitored.
    • Tumor vascularization at the invading margins was assessed.

    Main Results:

    • I.C.R.F. 159 completely inhibited metastasis formation.
    • The drug had minimal impact on the growth rate of the primary tumor.
    • Inhibition of metastasis was attributed to I.C.R.F. 159's effect on tumor angiogenesis.
    • This represents the first reported instance of a drug specifically targeting blood-borne tumor cell dissemination.

    Conclusions:

    • I.C.R.F. 159 is a potent inhibitor of metastasis in Lewis lung carcinoma.
    • The drug's mechanism involves the disruption of tumor angiogenesis.
    • I.C.R.F. 159 demonstrates a novel therapeutic strategy for preventing cancer spread.

    Related Concept Videos